Overall rank by patents
#18,153
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Suzhou Miracpharma Technology Co., Ltd.
USPTO PatentsView assignee record - 16 granted patents across 7 technology areas, active 2016–2019. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07D (HETEROCYCLIC COMPOUNDS).
16
Total patents granted
7
CPC technology areas
9.4
Avg claims per patent
-100%
5-year filing velocity
The verdict
Suzhou holds 16 US patents across 7 technology areas, rank #18,153 of 50,000 tracked assignees.
- #18,153
- of 50,000 US assignees by volume
- Top 84%
- by Innovation Score (24.8/100)
- 9.4
- avg claims per patent
- -100%
- filing velocity, last 5 yrs
Portfolio overview
Suzhou Miracpharma Technology Co., Ltd. has been granted 16 US utility patents between 2016 and 2019, placing Suzhou Miracpharma Technology Co., Ltd. at rank #18,153 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.4 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a Foreign Corporation, Suzhou Miracpharma Technology Co., Ltd. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 24.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 16 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Suzhou Miracpharma Technology Co., Ltd.'s 9.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Suzhou Miracpharma Technology Co., Ltd. against peers pursuing similar technology classes.
How does Suzhou compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Suzhou Miracpharm… ◀ 16
Suzhou Miracpharma Technology Co., Ltd.
16 patents
What this shows Suzhou holds 16 patents, placing it at rank #18,153 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Suzhou's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
25 Top 84% higher than 16% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2016–2019
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 6.3% |
| 2017 | 6 | 37.5% |
| 2018 | 6 | 37.5% |
| 2019 | 3 | 18.8% |
Which technologies does Suzhou Miracpharma Technology Co., Ltd. patent most?
Top 7 of 7 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Declining
Frequently Asked Questions
How many patents does Suzhou Miracpharma Technology Co., Ltd. hold?
Suzhou Miracpharma Technology Co., Ltd. holds 16 US granted patents filed between 2016 and 2019, spanning 7 technology areas.
What is Suzhou Miracpharma Technology Co., Ltd.'s Innovation Score?
Suzhou Miracpharma Technology Co., Ltd. has an Innovation Score of 24.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Suzhou Miracpharma Technology Co., Ltd. focus on?
Suzhou Miracpharma Technology Co., Ltd.'s top technology area is C07D (HETEROCYCLIC COMPOUNDS) with 15 patents. The company has filed patents in 7 CPC subclasses total.
Is Suzhou Miracpharma Technology Co., Ltd.'s patent filing rate increasing or decreasing?
Suzhou Miracpharma Technology Co., Ltd.'s recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Suzhou Miracpharma Technology Co., Ltd.'s patents?
Suzhou Miracpharma Technology Co., Ltd.'s patents average 9.4 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Suzhou Miracpharma Technology Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Suzhou's 16 grants land it in the top 84% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Suzhou ranks #18,153 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07D - see who else leads that technology area. C07D leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
C07D technology
Suzhou Miracpharma Technology Co., Ltd.'s primary CPC class, all holders and yearly trends
Top 50 patent holders
See where Suzhou Miracpharma Technology Co., Ltd. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.